NYSE:ABBV News 23 August 2025

AbbVie (ABBV) Stock Today, November 26, 2025: Share Price Dip Amid FDA Win, Medicare Drug Price Cuts and Bullish Options Signals

AbbVie Inc. (NYSE: ABBV) is trading lower today, but the big pharma giant remains near multi-year highs as investors digest a powerful mix of good news (a major FDA approval, strong Q3 numbers) and growing policy headwinds from U.S. Medicare

26 November 2025

AbbVie (ABBV) Stock Today: Price, Analyst Views, Medicare News and New Biotech Award – November 25, 2025

AbbVie Inc. (NYSE: ABBV) ended Tuesday, November 25, 2025, on a firmer footing, closing at $231.80, up about 1.0% on the day and recovering some of Monday’s pullback. The move came amid a flurry of fresh headlines: U.S. Medicare confirmed

25 November 2025

Analyst Opinions · Biotech News · Investment Insights · Medicare Updates · NYSE:ABBV · Stock Market

AbbVie Stock Today (ABBV): Near Record Highs on New Cancer Approval, Raised Guidance and Dividend Hike – November 23, 2025

Published: November 23, 2025 – Ticker: NYSE: ABBVThis article is for informational purposes only and is not financial advice. Key takeaways AbbVie stock price today: still near the top of its range U.S. markets are closed today (Sunday), so the

23 November 2025

Company Earnings · Dividends · Investing · NYSE:ABBV · Pharma News · Stock Market

AbbVie’s Bull Run: Why This $400B Pharma Giant’s Stock Is Just Getting Started

Stock Performance & Technical Trends AbbVie’s stock has been a standout performer in 2025. Shares currently hover around $228–$229, up roughly 28–30% since January and near their highest levels on record ts2.tech reportify.cn. This vastly outperforms both the S&P 500

31 October 2025

Financial Analysis · Healthcare Industry · Investment Strategies · NYSE:ABBV · Pharmaceuticals · Stock Market

AbbVie Stock Skyrocketing? Analysts Say This $230 Biotech Giant Is Just Getting Started

AbbVie (ABBV) Stock Up 28% YTD as New Drug Wins and Analyst Upgrades Fuel Optimism

Key Facts (as of Oct. 23, 2025): Stock Price and Recent Performance AbbVie’s stock has been a standout in 2025. Shares currently hover around $228–$229, up roughly 28% since January and near their highest levels on record directorstalkinterviews.com. By comparison,

23 October 2025

Investment · Market Analysis · NYSE:ABBV · Pharmaceuticals · Stocks · Wall Street

MindMed Stock Skyrockets on Psychedelic Breakthroughs – What’s Driving the MNMD Surge?

MindMed Stock Soars 15% to 52-Week High on Psychedelic Breakthrough – What’s Next for MNMD?

Key Facts – October 18, 2025 MNMD Stock Rallies to New Highs on Heavy Volume MindMed’s stock has been on fire, vastly outperforming the broader market in recent weeks. Shares rocketed to a 52-week high of $13.09 on October 14,

18 October 2025

Biotechnology · Financial News · Investing · NASDAQ:CMPS · NASDAQ:MNMD · NYSE:ABBV · Psychedelics · Stock Market

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 18.10.2025

ENDEDLive coverage has endedEnded: October 20, 2025, 6:00 AM EDT Could $500 Monthly Invested Turn Into a $680K Dividend-Paying Portfolio With This Vanguard ETF? October 19, 2025, 5:56 AM EDT. One Vanguard ETF stands out for income investors: the Vanguard

18 October 2025

Economic Trends · Financial News · Investing · Market Analysis · NASDAQ:ASML · NASDAQ:AVGO · NASDAQ:META · NASDAQ:TWLO · NYSE:ABBV · NYSE:BAC · NYSE:CVX · NYSE:HD · NYSE:JNJ · NYSE:JPM · NYSE:PG · NYSE:WMT · NYSE:XOM · Stock Market

AbbVie Stock Skyrocketing? Analysts Say This $230 Biotech Giant Is Just Getting Started

Stock Performance & Recent Trends AbbVie’s stock closed at $230.88 on Oct. 10, 2025 marketbeat.com. Over the prior five trading days it moved modestly: Oct. 7: $232.83; Oct. 8: $231.24; Oct. 9: $230.69; Oct. 10: $230.50 investing.com. Notably, on Sept. 30 ABBV hit a 52-week

11 October 2025

Biotech · Financial Analysis · Investing · NYSE:ABBV · Pharmaceuticals · Stock Market

Obesity Pill Breakthrough, Gene Therapy Triumph & Billion-Dollar Psychedelic Bet – Global Biotech & Health Highlights (Aug 26–27, 2025)

Key Facts Sources

27 August 2025

Biotech · Gene Therapy · Health · NASDAQ:PGEN · NYSE:ABBV · NYSE:LLY · Obesity · Psychedelics

Billion-Dollar Pharma Deals, Biotech Breakthroughs & Global Health Alerts – Biotech & Health News Roundup (Aug 25–26, 2025)

Biotech & Pharma Industry Updates Regulatory & Drug Approvals Clinical Trials & Innovations Medical Research Highlights Health Policy & Government Public Health & Global Health Alerts Sources: This report draws on recent press releases and expert commentary from Reuters, AP,

26 August 2025

Biotech · Global Alerts · Health · NYSE:ABBV · Pharma · Science News

Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

Regulatory Approvals & Clinical Milestones Pharma & Biotech Industry Moves Startups & Innovation Highlights Medical Research & Innovation Public Health & Policy Developments Sources: Ionis HAE drug approval pharmexec.com biopharmadive.com; BioPharmaDive on Dawnzera pricing and positioning biopharmadive.com biopharmadive.com; AbbVie Rinvoq

23 August 2025

Biotech · Health News · Medical Research · NASDAQ:IONS · NASDAQ:KALV · NASDAQ:SRRK · NYSE:ABBV · NYSE:LLY · Pharmaceuticals · Public Health

NYSE:ABBV News 23 August 2025 - 26 November 2025